EZH2 inhibitors for treating lymphoma

1. A method for treating a germinal center-derived lymphoma in a subject in need thereof comprising administering a therapeutically effective amount of an EZH2 inhibitor and a therapeutically effective amount of a standard of care agent, wherein the EZH2 inhibitor is of Formula (I):

or a pharmaceutically acceptable salt thereof; wherein:

R 701 is H, F, OR 707 , NHR 707 , —(C≡C)—(CH 2 ) n7 —R 708 , phenyl, 5- or 6-membered heteroaryl, C 3-8 cycloalkyl, or 4-7 membered heterocycloalkyl containing 1-3 heteroatoms, wherein the phenyl, 5- or 6-membered heteroaryl, C 3-8 cycloalkyl or 4-7 membered heterocycloalkyl each independently is optionally substituted with one or more groups selected from halo, C 1-3 alkyl, OH, O—C 1-6 alkyl, NH—C 1-6 alkyl, and, C 1-3 alkyl substituted with C 3-8 cycloalkyl or 4-7 membered heterocycloalkyl containing 1-3 heteroatoms, wherein each of the O—C 1-6 alkyl and NH—C 1-6 alkyl is optionally substituted with hydroxyl, O—C 1-3 alkyl or NH—C 1-3 alkyl, each of the O—C 1-3 alkyl and NH—C 1-3 alkyl being optionally further substituted with O—C 1-3 alkyl or NH—C 1-3 alkyl;

each of R 702 and R 703 independently is H, halo, C 1-4 alkyl, C 1-6 alkoxyl or C 6-C10 aryloxy, each optionally substituted with one or more halo;

each of R 704 and R 705 independently is C 1-4 alkyl;

R 706 is cyclohexyl substituted by N(C 1-4 alkyl) 2 wherein one or both of the C 1-4 alkyl is optionally substituted with C 1-6 alkoxy; or R 706 is tetrahydropyranyl;

R 707 is C 1-4 alkyl optionally substituted with one or more groups selected from hydroxyl, C 1-4 alkoxy, amino, mono- or di-C 1-4 alkylamino, C 3-8 cycloalkyl, and 4-7 membered heterocycloalkyl containing 1-3 heteroatoms, wherein the C 3-8 cycloalkyl or 4-7 membered heterocycloalkyl each independently is further optionally substituted with C 1-3 alkyl;

R 708 is C 1-4 alkyl optionally substituted with one or more groups selected from OH, halo, and C 1-4 alkoxy, 4-7 membered heterocycloalkyl containing 1-3 heteroatoms, or O—C 1-6 alkyl, wherein the 4-7 membered heterocycloalkyl can be optionally further substituted with OH or C 1-6 alkyl; and

n 7 is 0, 1, or 2; and

wherein the standard of care agent is selected from Alisertib, Enzastaurin, Vemurafenib, Ruxolitinib, Fedratinib, Tofacitinib, OG-L002, and GSK J4.

2. The method of claim 1 , wherein the germinal center-derived lymphoma is an EZH2 wild type germinal center B-cell lymphoma.

3. The method of claim 1 , wherein the germinal center-derived lymphoma is an EZH2 mutant germinal center B-cell lymphoma.

4. The method of claim 1 , wherein the germinal center-derived lymphoma is diffuse large B-cell lymphoma, follicular lymphoma, Burkitt's lymphoma or Non-Hodgkin's Lymphoma of germinal center B cell subtype.

5. The method of claim 1 , wherein the EZH2 inhibitor is tazemetostat:

or a pharmaceutically acceptable salt thereof.

6. The method of claim 1 , wherein the EZH2 inhibitor is administered to the subject at a dose of about 100 mg to about 3200 mg daily.

7. The method of claim 1 , wherein the EZH2 inhibitor and the standard of care agent are administered simultaneously or sequentially.

8. A method for treating Primary Mediastinal Large B-Cell Lymphoma (PMBCL) in a subject in need thereof comprising a step of administering a therapeutically effective amount of an EZH2 inhibitor and a therapeutically effective amount of a standard of care agent, wherein the EZH2 inhibitor is of Formula (I):

or a pharmaceutically acceptable salt thereof; wherein:

R 701 is H, F, OR 707 , NHR 707 , —(C≡C)—(CH 2 ) n7 —R 708 , phenyl, 5- or 6-membered heteroaryl, C 3-8 cycloalkyl, or 4-7 membered heterocycloalkyl containing 1-3 heteroatoms, wherein the phenyl, 5- or 6-membered heteroaryl, C 3-8 cycloalkyl or 4-7 membered heterocycloalkyl each independently is optionally substituted with one or more groups selected from halo, C 1-3 alkyl, OH, O—C 1-6 alkyl, NH—C 1-6 alkyl, and, C 1-3 alkyl substituted with C 3-8 cycloalkyl or 4-7 membered heterocycloalkyl containing 1-3 heteroatoms, wherein each of the O—C 1-6 alkyl and NH—C 1-6 alkyl is optionally substituted with hydroxyl, O—C 1-3 alkyl or NH—C 1-3 alkyl, each of the O—C 1-3 alkyl and NH—C 1-3 alkyl being optionally further substituted with O—C 1-3 alkyl or NH—C 1-3 alkyl;

each of R 702 and R 703 independently is H, halo, C 1-4 alkyl, C 1-6 alkoxyl or C 6-C10 aryloxy, each optionally substituted with one or more halo;

each of R 704 and R 705 independently is C 1-4 alkyl;

R 706 is cyclohexyl substituted by N(C 1-4 alkyl) 2 wherein one or both of the C 1-4 alkyl is optionally substituted with C 1-6 alkoxy; or R 706 is tetrahydropyranyl;

R 707 is C 1-4 alkyl optionally substituted with one or more groups selected from hydroxyl, C 1-4 alkoxy, amino, mono- or di-C 1-4 alkylamino, C 3-8 cycloalkyl, and 4-7 membered heterocycloalkyl containing 1-3 heteroatoms, wherein the C 3-8 cycloalkyl or 4-7 membered heterocycloalkyl each independently is further optionally substituted with C 1-3 alkyl;

R 708 is C 1-4 alkyl optionally substituted with one or more groups selected from OH, halo, and C 1-4 alkoxy, 4-7 membered heterocycloalkyl containing 1-3 heteroatoms, or O—C 1-6 alkyl, wherein the 4-7 membered heterocycloalkyl can be optionally further substituted with OH or C 1-6 alkyl; and

n 7 is 0, 1, or 2; and

wherein the standard of care agent is selected from Alisertib, Enzastaurin, Vemurafenib, Ruxolitinib, Fedratinib, Tofacitinib, OG-L002, and GSK J4.

9. The method of claim 8 , wherein the EZH2 inhibitor is tazemetostat:

or a pharmaceutically acceptable salt thereof.

10. The method of claim 8 , wherein the EZH2 inhibitor is administered to the subject at a dose of about 100 mg to about 3200 mg daily.

11. The method of claim 8 , wherein the EZH2 inhibitor and the standard of care agent are administered simultaneously or sequentially.

12. A method of selecting a patient for the method of claim 1 , wherein the patient is selected based on the expression profile of one or more genes selected from the group consisting of EZH2, BCL6, and BCL2.

13. The method of claim 12 , wherein the method further comprises a step of detecting levels of histone methylation in a skin biopsy.

14. The method of claim 13 , wherein the histone methylation is H3K27 trimethylation.